BRAF and thyroid gland carcinoma: Further, as shown in thyroid cancer cells harboring BRAFV600E mutation, the binding of the co-chaperone BAG3 to BRAF protected it from degradation by inhibiting HSP70-mediated delivery to the proteasome [57, 58].